Prospective economic evaluation of phase III trial comparing irinotecan with infusional 5-FU in patients with advanced colorectal cancer

被引：0
|
作者：
Schmitt, C
Jolain, B
Van Cutsem, E
机构：
[1] UZ Gasthuisberg, Leuwen, Belgium
[2] Rhone Poulenc Rorer, Antony, France
[3] ARCOS, Issy Les Moulineaux, France
来源：
MEDICAL DECISION MAKING | 1998年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：484 / 484
页数：1
相关论文
共 50 条
  • [41] Tissue biomarkers (BIOM) in colon cancer (COC): The translational study on the randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (pts)
    Roth, A. D.
    Tejpar, S.
    Yan, P.
    Fiocca, R.
    Dietrich, D.
    Bodoky, G.
    Labianca, R.
    Cunningham, D.
    Van Cutsem, E.
    Bosman, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [43] Randomised phase III trial comparing irinotecan plus capecitabine (XELIRI Regimen) vs. irinotecan, 5-Fu and folinic acid (Saltz regimen) as first-line treatment in patients (PTS) with metastatic colorectal cancer (MCRC)
    Munoz, Alberto
    Salud, Antonieta
    Garcia Giron, Carlos
    Murias, Adolfo
    Burillo, Miguel A.
    Arizcun, Alberto
    Gutierrez, David
    Pujol, Eduardo
    ANNALS OF ONCOLOGY, 2006, 17 : 120 - 120
  • [44] RANDOMIZED TRIAL OF MELPHALAN PLUS 5-FLUOROURACIL (5-FU) VERSUS METHYL-CCNU PLUS 5-FU IN PATIENTS WITH ADVANCED COLORECTAL CANCER
    BERMAN, R
    GILES, GR
    MALHOTRA, A
    BIRD, GG
    GAJJAR, PD
    BUNCH, GA
    HALL, R
    CANCER TREATMENT REPORTS, 1978, 62 (03): : 457 - 459
  • [45] Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer
    Leonard, P
    Seymour, MT
    James, R
    Hochhauser, D
    Ledermann, JA
    BRITISH JOURNAL OF CANCER, 2002, 87 (11) : 1216 - 1220
  • [46] Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer
    P Leonard
    M T Seymour
    R James
    D Hochhauser
    J A Ledermann
    British Journal of Cancer, 2002, 87 : 1216 - 1220
  • [47] Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas - a multicenter phase II trial (GBFiri).
    Feisthammel, J
    Schoppmeyer, K
    Wiedmann, M
    Zinke, J
    Mossner, J
    Schulze, M
    Caca, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 352S - 352S
  • [48] PHASE-III STUDY OF 5-FU AND CARMUSTINE VERSUS 5-FU, CARMUSTINE, AND DOXORUBICIN IN ADVANCED GASTRIC-CANCER
    SCHNITZLER, G
    QUEISSER, W
    HEIM, ME
    KONIG, H
    KATZ, R
    FRITZE, D
    HERRMANN, R
    ARNOLD, H
    HENSS, H
    TRUX, FA
    BLOCH, R
    KEYMLING, M
    WOLKEWITZ, KD
    FRITSCH, H
    HANISCH, I
    BRUMEN, L
    EDLER, L
    CANCER TREATMENT REPORTS, 1986, 70 (04): : 477 - 479
  • [49] Phase II study of 5-FU/LV/lrinotecan in combination with regional hyperthermia (RHT) in 5-FU/Lv refractory patients with advanced colorectal cancer
    Krych, M
    Lindner, LH
    Abele, S
    Abdel-Rahman, S
    Fahn, W
    Milani, V
    Braun, S
    Stockheim, B
    Heinemann, V
    Issels, RD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 301S - 301S
  • [50] Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
    M P Saunders
    M Hogg
    B Carrington
    A-M Sjursen
    J Allen
    J Beech
    R Swindell
    J W Valle
    British Journal of Cancer, 2004, 91 : 1447 - 1452
12345